Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced the signature of a license and option agreement with ProfoundBio, an emerging oncology biotherapeutics company.
Citryll is pleased to announce that it has recently secured grant of patents in China (in March 2021), in Australia (in May 2021), and in the USA (in July 2021) relating to the use of therapeutic Anti-Citrullinated Protein Antibodies (tACPAs) to treat one of our lead indications, idiopathic pulmonary fibrosis (IPF).
In partnership with GHO Capital, ARDENA announced a major €35 million investment for expansion across its European operations. The investment will future proof offerings for the biopharma and emerging biotechnology sectors and positions Ardena to become a leading global CDMO, offering end-to-end solutions spanning the full pharma development lifecycle.
DIANT Continuous Nanoparticle Manufacturing System Integrates With InProcess-LSP NanoFlowSizer For Size Characterization.
DIANT Pharma Inc. (DIANT), a startup company that provides a turnkey solution for continuous manufacturing of nanoparticles, has the exclusive right to integrate the NanoFlowSizer into the DIANT system, providing a major advantage to DIANT customers. The DIANT system has multiple flow options, up to 100 LPM, and has multiple add-on modules with integrated process analytical technology operating as a single, closed-system.
Citryll’s first in class antibody drug candidate CIT-013 for autoimmune and chronic inflammatory diseases is beginning its bioanalytical phase at Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO).
Dr. Saman Honarnejad, Director of Drug Discovery at Pivot Park Screening Centre has been appointed as an external member of
Aspen will test the evacuation signal on TTP (Tanker truckpark) on Wednesday July 7th. This evacuation signal will sound for a few seconds each time, so that the nuisance for the environment is as minimal as possible. The evacuation signal will be heard within times on Wednesday 7 July:
Between 9 a.m. and 10 a.m. and between 2 pm and 4 pm.
Ardena is pleased to announce that a Commercial Agency Agreement for South Korea has been signed with the company Keyfronbio Co., Ltd.
Voor de bouw van een nieuw pand genaamd Grizzly op Pivot Park in Oss verstrekt de provincie een lening van 37,1 miljoen euro aan de holding van het park. Pivot Park ontwikkelt zich snel en dreig uit haar jasje te groeien. Deze ontwikkeling is dan ook nodig om nu en in toekomst een campus te zijn die aan de verwachtingen en eisen van gebruikers voldoet en om een leidende rol in de wereld van farmacie te kunnen blijven spelen.
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.